Lilly To Focus Mainly On Pipeline Development As It Faces Steep Patent Cliff
With generic competition around the corner for blockbusters like Zyprexa, Lilly can't count on many more quarters like the past one's 16 percent net income growth.
With generic competition around the corner for blockbusters like Zyprexa, Lilly can't count on many more quarters like the past one's 16 percent net income growth.